Each year in the United States, breast cancer is diagnosed inmore than 170,000 women.1 Despite this substantial burden ofdisease, however, assessment of breast-cancer risk has receivedvery little attention outside the oncology clinic.2,3 In primarycare, the main result of the recognition of individual variationin breast-cancer risk is the use of age to determine recommendationsregarding mammography (older age is a strong risk factor forbreast cancer).4
Recent developments in the ability to predict and alter breast-cancerrisk warrant a new look at the role of assessment of this riskin primary care. Physicians must become adept . . . [Full Text of this Article]
Why Evaluate Breast-Cancer Risk?
Decisions about Postmenopausal Hormone-Replacement Therapy
Decisions about the Use of Mammography for Women 40 to 49 Years of Age
Decisions about the Use of Tamoxifen for the Prevention of Breast Cancer
Decisions about Prophylactic Mastectomy
How to Evaluate Breast-Cancer Risk
Average Risk
Epidemiologic Risk Factors
Risk-Prediction Models
Genetic-Susceptibility Testing
Selecting a Prediction Method
Source Information
From the Department of Medicine (K.A., A.E., B.W.) and the Center for Clinical Epidemiology and Biostatistics (K.A.), University of Pennsylvania School of Medicine; the University of Pennsylvania Cancer Center (K.A., A.E., B.W.); and the Leonard Davis Institute of Health Economics, University of Pennsylvania (K.A.) all in Philadelphia.
Address reprint requests to Dr. Armstrong at 1233 Blockley Hall, 423 Guardian Dr., Philadelphia, PA 19104-6021, or at karmstro@mail.med.upenn.edu.
References
This article has been cited by other articles:
Qaseem, A., Snow, V., Sherif, K., Aronson, M., Weiss, K. B., Owens, D. K., for the Clinical Efficacy Assessment Subcommittee,
(2007). Screening Mammography for Women 40 to 49 Years of Age: A Clinical Practice Guideline from the American College of Physicians. ANN INTERN MED
146: 511-515
[Abstract][Full Text]
Armstrong, K., Moye, E., Williams, S., Berlin, J. A., Reynolds, E. E.
(2007). Screening Mammography in Women 40 to 49 Years of Age: A Systematic Review for the American College of Physicians. ANN INTERN MED
146: 516-526
[Abstract][Full Text]
Dorval, M., Gauthier, G., Maunsell, E., Dugas, M. J., Rouleau, I., Chiquette, J., Plante, M., Laframboise, R., Gaudet, M., Bridge, P. J., INHERIT BRCAs, , Simard, J.
(2005). No Evidence of False Reassurance among Women with an Inconclusive BRCA1/2 Genetic Test Result. Cancer Epidemiol. Biomarkers Prev.
14: 2862-2867
[Abstract][Full Text]
Elmore, J. G., Gigerenzer, G.
(2005). Benign Breast Disease -- The Risks of Communicating Risk. NEJM
353: 297-299
[Full Text]
Chlebowski, R. T., Chen, Z., Anderson, G. L., Rohan, T., Aragaki, A., Lane, D., Dolan, N. C., Paskett, E. D., McTiernan, A., Hubbell, F. A., Adams-Campbell, L. L., Prentice, R.
(2005). Ethnicity and Breast Cancer: Factors Influencing Differences in Incidence and Outcome. JNCI J Natl Cancer Inst
97: 439-448
[Abstract][Full Text]
Weiss, J. R., Moysich, K. B., Swede, H.
(2005). Epidemiology of Male Breast Cancer. Cancer Epidemiol. Biomarkers Prev.
14: 20-26
[Abstract][Full Text]
Cannistra, S. A.
(2004). Cancer of the Ovary. NEJM
351: 2519-2529
[Full Text]
Sifri, R., Gangadharappa, S., Acheson, L. S.
(2004). Identifying and Testing for Hereditary Susceptibility to Common Cancers. CA Cancer J Clin
54: 309-326
[Abstract][Full Text]
Lewis, C. L., Kinsinger, L. S., Harris, R. P., Schwartz, R. J.
(2004). Breast Cancer Risk in Primary Care: Implications for Chemoprevention. Arch Intern Med
164: 1897-1903
[Abstract][Full Text]
Vacek, P. M., Geller, B. M.
(2004). A Prospective Study of Breast Cancer Risk Using Routine Mammographic Breast Density Measurements. Cancer Epidemiol. Biomarkers Prev.
13: 715-722
[Abstract][Full Text]
Contegiacomo, A., Pensabene, M., Capuano, I., Tauchmanova, L., Federico, M., Turchetti, D., Cortesi, L., Marchetti, P., Ricevuto, E., Cianci, G., Venuta, S., Barbieri, V., Silingardi, V.
(2004). An oncologist-based model of cancer genetic counselling for hereditary breast and ovarian cancer. Ann Oncol
15: 726-732
[Abstract][Full Text]
Tsao, A. S., Kim, E. S., Hong, W. K.
(2004). Chemoprevention of Cancer. CA Cancer J Clin
54: 150-180
[Abstract][Full Text]
Armstrong, K., Schwartz, J. S., Randall, T., Rubin, S. C., Weber, B.
(2004). Hormone Replacement Therapy and Life Expectancy After Prophylactic Oophorectomy in Women With BRCA1/2 Mutations: A Decision Analysis. JCO
22: 1045-1054
[Abstract][Full Text]
Verkooijen, H. M., Fioretta, G., Chappuis, P. O., Vlastos, G., Sappino, A. P., Benhamou, S., Bouchardy, C.
(2004). Set-up of a population-based familial breast cancer registry in Geneva, Switzerland: validation of first results. Ann Oncol
15: 350-353
[Abstract][Full Text]
Hampel, H, Sweet, K, Westman, J A, Offit, K, Eng, C
(2004). Referral for cancer genetics consultation: a review and compilation of risk assessment criteria. J. Med. Genet.
41: 81-91
[Abstract][Full Text]
Halls, S. B., Crystal, P., Karakis, I., Strano, S., Koretz, M.
(2004). Statistical Comparison of Proportions. Am. J. Roentgenol.
182
: 259-260
[Full Text]
Morris, E. A., Liberman, L., Ballon, D. J., Robson, M., Abramson, A. F., Heerdt, A., Dershaw, D. D.
(2003). MRI of Occult Breast Carcinoma in a High-Risk Population. Am. J. Roentgenol.
181: 619-626
[Abstract][Full Text]
Liberman, L., Morris, E. A., Dershaw, D. D., Abramson, A. F., Tan, L. K.
(2003). Ductal Enhancement on MR Imaging of the Breast. Am. J. Roentgenol.
181: 519-525
[Abstract][Full Text]
Dalpe, R., Bouchard, L., Houle, A.-J., Bedard, L.
(2003). Watching the Race to Find the Breast Cancer Genes. Science Technology Human Values
28: 187-216
[Abstract]
Bach, P. B., Kattan, M. W., Thornquist, M. D., Kris, M. G., Tate, R. C., Barnett, M. J., Hsieh, L. J., Begg, C. B.
(2003). Variations in Lung Cancer Risk Among Smokers. JNCI J Natl Cancer Inst
95: 470-478
[Abstract][Full Text]
Pichert, G., Bolliger, B., Buser, K., Pagani, O.
(2003). Evidence-based management options for women at increased breast/ovarian cancer risk. Ann Oncol
14: 9-19
[Abstract][Full Text]
Mann, R. J., Keri, R. A., Nilson, J. H.
(2003). Consequences of Elevated Luteinizing Hormone on Diverse Physiological Systems: Use of the LH{beta}CTP Transgenic Mouse as a Model of Ovarian Hyperstimulation-induced Pathophysiology. Recent Prog Horm Res
58: 343-375
[Abstract][Full Text]
Chandawarkar, R. Y., Guyton, D. P.
(2002). Oncologic Mathematics: Evolution of a New Specialty. Arch Surg
137: 1428-1434
[Abstract][Full Text]
Guttmacher, A. E., Collins, F. S.
(2002). Genomic Medicine -- A Primer. NEJM
347: 1512-1520
[Full Text]
Milliken, E. L., Ameduri, R. K., Landis, M. D., Behrooz, A., Abdul-Karim, F. W., Keri, R. A.
(2002). Ovarian Hyperstimulation by LH Leads to Mammary Gland Hyperplasia and Cancer Predisposition in Transgenic Mice. Endocrinology
143: 3671-3680
[Abstract][Full Text]
Sinclair, A.
(2002). Genetics 101: detecting mutations in human genes. CMAJ
167: 275-279
[Full Text]
Chlebowski, R. T., Col, N., Winer, E. P., Collyar, D. E., Cummings, S. R., Vogel, V. G. III, Burstein, H. J., Eisen, A., Lipkus, I., Pfister, D. G.
(2002). American Society of Clinical Oncology Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene, and Aromatase Inhibition. JCO
20: 3328-3343
[Abstract][Full Text]
Kinsinger, L. S., Harris, R., Woolf, S. H., Sox, H. C., Lohr, K. N.
(2002). Chemoprevention of Breast Cancer: A Summary of the Evidence for the U.S. Preventive Services Task Force. ANN INTERN MED
137: 59-69
[Abstract][Full Text]
Thomas, D. B., Carter, R. A., Bush, W. H. Jr., Ray, R. M., Stanford, J. L., Lehman, C. D., Daling, J. R., Malone, K., Davis, S.
(2002). Risk of Subsequent Breast Cancer in Relation to Characteristics of Screening Mammograms from Women Less Than 50 Years of Age. Cancer Epidemiol. Biomarkers Prev.
11: 565-571
[Abstract][Full Text]
Love, R. R.
(2002). Breast Cancer Prevention. The Oncologist
7: 100-102
[Full Text]
Powell, B. L., van Staveren, I. L., Roosken, P., Grieu, F., Berns, E. M.J.J., Iacopetta, B.
(2002). Associations between common polymorphisms in TP53 and p21WAF1/Cip1 and phenotypic features of breast cancer. Carcinogenesis
23: 311-315
[Abstract][Full Text]
Stoutjesdijk, M. J., Boetes, C., Jager, G. J., Beex, L., Bult, P., Hendriks, J. H. C. L., Laheij, R. J. F., Massuger, L., van Die, L. E., Wobbes, T., Barentsz, J. O.
(2001). Magnetic Resonance Imaging and Mammography in Women With a Hereditary Risk of Breast Cancer. JNCI J Natl Cancer Inst
93: 1095-1102
[Abstract][Full Text]
Bastian, L. A., Lipkus, I. M., Kuchibhatla, M. N., Weng, H. H., Halabi, S., Ryan, P. D., Skinner, C. S., Rimer, B. K.
(2001). Women's Interest in Chemoprevention for Breast Cancer. Arch Intern Med
161: 1639-1644
[Abstract][Full Text]
Ziv, E., Cauley, J., Morin, P. A., Saiz, R., Browner, W. S.
(2001). Association Between the T29->C Polymorphism in the Transforming Growth Factor {beta}1 Gene and Breast Cancer Among Elderly White Women: The Study of Osteoporotic Fractures. JAMA
285: 2859-2863
[Abstract][Full Text]
Levine, M., Moutquin, J.-M., Walton, R., Feightner, J.
(2001). Chemoprevention of breast cancer: A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. CMAJ
164: 1681-1690
[Abstract][Full Text]
McTiernan, A., Kuniyuki, A., Yasui, Y., Bowen, D., Burke, W., Culver, J. B., Anderson, R., Durfy, S.
(2001). Comparisons of Two Breast Cancer Risk Estimates in Women with a Family History of Breast Cancer. Cancer Epidemiol. Biomarkers Prev.
10: 333-338
[Abstract][Full Text]
Burstein, H. J., Winer, E. P.
(2000). Primary Care for Survivors of Breast Cancer. NEJM
343: 1086-1094
[Full Text]
Chlebowski, R. T.
(2000). Reducing the Risk of Breast Cancer. NEJM
343: 191-198
[Full Text]